Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study

M. Mego; R. A. Huddart; J. Voortman; M. Ong; C. Gedye; H. Gurney; A. P. Fay; A. Bamias; B. Mellado Gonzalez; Y. Loriot; A. S. Merseburger; D. Castellano Gauna; S. de Ducla; J. Pavlova; S. Fear; C. N. Sternberg

doi:10.1016/j.annonc.2020.08.838

Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study

M. Mego, R. A. Huddart, J. Voortman, M. Ong, C. Gedye, H. Gurney, A. P. Fay, A. Bamias, B. Mellado Gonzalez, Y. Loriot, A. S. Merseburger, D. Castellano Gauna, S. de Ducla, J. Pavlova, S. Fear, C. N. Sternberg

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	S591-S591
Journal	Annals of Oncology
Volume	31
DOIs	https://doi.org/10.1016/j.annonc.2020.08.838
Publication status	Published - Sep 2020

Access to Document

10.1016/j.annonc.2020.08.838

Cite this

Mego, M., Huddart, R. A., Voortman, J., Ong, M., Gedye, C., Gurney, H., Fay, A. P., Bamias, A., Mellado Gonzalez, B., Loriot, Y., Merseburger, A. S., Castellano Gauna, D., de Ducla, S., Pavlova, J., Fear, S., & Sternberg, C. N. (2020). Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study. Annals of Oncology, 31, S591-S591. https://doi.org/10.1016/j.annonc.2020.08.838

@article{87c55a6e4faf48edaea227cb08420fe9,

title = "Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study",

author = "M. Mego and Huddart, {R. A.} and J. Voortman and M. Ong and C. Gedye and H. Gurney and Fay, {A. P.} and A. Bamias and {Mellado Gonzalez}, B. and Y. Loriot and Merseburger, {A. S.} and {Castellano Gauna}, D. and {de Ducla}, S. and J. Pavlova and S. Fear and Sternberg, {C. N.}",

year = "2020",

month = sep,

doi = "10.1016/j.annonc.2020.08.838",

language = "English",

volume = "31",

pages = "S591--S591",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Mego, M, Huddart, RA, Voortman, J, Ong, M, Gedye, C, Gurney, H, Fay, AP, Bamias, A, Mellado Gonzalez, B, Loriot, Y, Merseburger, AS, Castellano Gauna, D, de Ducla, S, Pavlova, J, Fear, S & Sternberg, CN 2020, 'Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study', Annals of Oncology, vol. 31, pp. S591-S591. https://doi.org/10.1016/j.annonc.2020.08.838

Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study. / Mego, M.; Huddart, R. A.; Voortman, J. et al.

In: Annals of Oncology, Vol. 31, 09.2020, p. S591-S591.

Research output: Contribution to journal › Meeting Abstract › Academic

TY - JOUR

T1 - Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study

AU - Mego, M.

AU - Huddart, R. A.

AU - Voortman, J.

AU - Ong, M.

AU - Gedye, C.

AU - Gurney, H.

AU - Fay, A. P.

AU - Bamias, A.

AU - Mellado Gonzalez, B.

AU - Loriot, Y.

AU - Merseburger, A. S.

AU - Castellano Gauna, D.

AU - de Ducla, S.

AU - Pavlova, J.

AU - Fear, S.

AU - Sternberg, C. N.

PY - 2020/9

Y1 - 2020/9

U2 - 10.1016/j.annonc.2020.08.838

DO - 10.1016/j.annonc.2020.08.838

M3 - Meeting Abstract

VL - 31

SP - S591-S591

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

ER -